National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic.
Institute of Photonics and Electronics of the Czech Academy of Sciences, Chaberska 57, 182 51, Prague, Czech Republic.
Neurochem Res. 2020 Apr;45(4):915-927. doi: 10.1007/s11064-020-02970-y. Epub 2020 Jan 29.
The nucleus-encoded 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) regulates cyclophilin D (cypD) in the mitochondrial matrix. CypD regulates opening of mitochondrial permeability transition pores. Both mechanisms may be affected by amyloid β peptides accumulated in mitochondria in Alzheimer's disease (AD). In order to clarify changes occurring in brain mitochondria, we evaluated interactions of both mitochondrial proteins in vitro (by surface plasmon resonance biosensor) and detected levels of various complexes of 17β-HSD10 formed in vivo (by sandwich ELISA) in brain mitochondria isolated from the transgenic animal model of AD (homozygous McGill-R-Thy1-APP rats) and in cerebrospinal fluid samples of AD patients. By surface plasmon resonance biosensor, we observed the interaction of 17β-HSD10 and cypD in a direct real-time manner and determined, for the first time, the kinetic parameters of the interaction (k 2.0 × 10 Ms, k 5.8 × 10 s, and K 3.5 × 10 M). In McGill-R-Thy1-APP rats compared to controls, levels of 17β-HSD10-cypD complexes were decreased and those of total amyloid β increased. Moreover, the levels of 17β-HSD10-cypD complexes were decreased in cerebrospinal fluid of individuals with AD (in mild cognitive impairment as well as dementia stages) or with Frontotemporal lobar degeneration (FTLD) compared to cognitively normal controls (the sensitivity of the complexes to AD dementia was 92.9%, that to FTLD 73.8%, the specificity to AD dementia equaled 91.7% in a comparison with the controls but only 26.2% with FTLD). Our results demonstrate the weakened ability of 17β-HSD10 to regulate cypD in the mitochondrial matrix probably via direct effects of amyloid β. Levels of 17β-HSD10-cypD complexes in cerebrospinal fluid seem to be the very sensitive indicator of mitochondrial dysfunction observed in neurodegeneration but unfortunately not specific to AD pathology. We do not recommend it as the new biomarker of AD.
核编码 17β-羟甾脱氢酶 10 型(17β-HSD10)调节线粒体基质中环孢菌素 D(cypD)。CypD 调节线粒体通透性转换孔的开放。这两种机制都可能受到阿尔茨海默病(AD)中线粒体中积累的淀粉样 β 肽的影响。为了阐明脑线粒体中发生的变化,我们在体外(通过表面等离子体共振生物传感器)评估了这两种线粒体蛋白的相互作用,并在 AD 的转基因动物模型(杂合 McGill-R-Thy1-APP 大鼠)和 AD 患者的脑脊液样本中检测了体内形成的各种 17β-HSD10 复合物的水平(通过夹心 ELISA)。通过表面等离子体共振生物传感器,我们以直接实时的方式观察到 17β-HSD10 和 cypD 的相互作用,并首次确定了相互作用的动力学参数(k 2.0×10 Ms、k 5.8×10 s 和 K 3.5×10 M)。与对照组相比,在 McGill-R-Thy1-APP 大鼠中,17β-HSD10-cypD 复合物的水平降低,总淀粉样 β 的水平增加。此外,与认知正常对照组相比,AD(轻度认知障碍和痴呆阶段)或额颞叶变性(FTLD)患者的脑脊液中 17β-HSD10-cypD 复合物的水平降低(17β-HSD10-cypD 复合物对 AD 痴呆的敏感性为 92.9%,对 FTLD 为 73.8%,与对照组相比,对 AD 痴呆的特异性为 91.7%,但与 FTLD 相比仅为 26.2%)。我们的结果表明,17β-HSD10 调节线粒体基质中环孢菌素 D 的能力减弱,可能是由于淀粉样 β 的直接作用。脑脊液中 17β-HSD10-cypD 复合物的水平似乎是神经退行性变中观察到的线粒体功能障碍的非常敏感的指标,但不幸的是,它不是 AD 病理学的特异性指标。我们不建议将其作为 AD 的新生物标志物。